PDS Biotechnology delivered a reduced net loss for Q3 2025 as lower research and development spending and controlled operating costs supported improved financial performance. The company ended the quarter with $26.2 million in cash and continued advancing multiple clinical programs, including seeking an expedited approval pathway for PDS0101.

Despite clinical advancements, PDS Biotech's Q2 2025 results reflected financial pressure from rising interest expenses. Operating costs were trimmed slightly, but the net loss deepened compared to Q2 2024.

PDS Biotechnology reported a net loss of $8.5 million for the first quarter of 2025, an improvement from the $10.6 million net loss in the same period last year, primarily due to increased benefit from income taxes and lower operating expenses. The company also highlighted progress in its clinical trials, including the initiation of the VERSATILE-003 Phase 3 trial and FDA clearance for a new IND application.

PDS Biotechnology reported a net loss of $37.6 million for the full year ended December 31, 2024, a reduction from the $42.9 million net loss in the prior year. This improvement was primarily driven by decreased operating expenses, partially offset by increased net interest expense. The company also initiated a pivotal Phase 3 clinical trial for Versamune® HPV in HPV16-positive head and neck cancer.

PDS Biotechnology reported a net loss of $10.7 million for the third quarter of 2024. The company is focused on advancing its clinical trials, particularly the VERSATILE-003 Phase 3 trial, and presented promising data from the IMMUNOCERV Phase 2 clinical trial.

PDS Biotech reported a net loss of $8.3 million for Q2 2024, a decrease from the $11.5 million net loss in Q2 2023, driven by lower operating expenses. The company is preparing to initiate a Phase 3 trial in Q4 2024.

PDS Biotechnology reported a net loss of $10.6 million for the first quarter of 2024, compared to a net loss of $9.7 million for the same period in 2023. R&D expenses increased to $6.7 million, and the company announced positive, updated data from its Phase 2 VERSATILE-002 clinical trial.

PDS Biotech reported a net loss of $42.9 million for the year ended December 31, 2023. The company is focusing its late-stage clinical strategy on the triple combination of PDS01ADC, PDS0101 (Versamune® HPV), and KEYTRUDA® in advanced head and neck cancer.

PDS Biotech reported a net loss of $10.8 million for the third quarter of 2023, driven by increased research and development and general and administrative expenses. The company's cash balance as of September 30, 2023, was $54.3 million, expected to sustain operations into Q3 2024.

PDS Biotech reported a net loss of $11.5 million for the second quarter of 2023, driven by increased research and development expenses. The company is progressing with its lead candidate, PDS0101, and anticipates initiating a Phase 3 clinical trial in Q4 2023.

PDS Biotech reported a net loss of $9.7 million, or $0.32 per share, for the first quarter of 2023, compared to a net loss of $8.5 million, or $0.32 per share, for the first quarter of 2022. The increase in net loss was primarily due to increased personnel, clinical studies, medical affairs, and manufacturing expenses. The company's cash and cash equivalents totaled $65.2 million as of March 31, 2023, which is expected to fund operations into the third quarter of 2024.

PDS Biotechnology announced the completion of key activities to initiate a global, multicenter Phase 3 registrational trial investigating the combination of PDS0101 and KEYTRUDA® in Q4 2023. The trial, named VERSATILE-003, will investigate the combination compared to KEYTRUDA® monotherapy for the treatment of unresectable, recurrent/metastatic human papillomavirus (HPV) 16-positive head and neck squamous cell carcinoma (HNSCC).

PDS Biotech reported a net loss of $7.4 million for the third quarter of 2022. The company highlighted the progress of its PDS0101 clinical programs and the strengthening of its balance sheet with a new loan agreement.

PDS Biotechnology reported a net loss of $5.8 million for the second quarter of 2022, compared to a net loss of $0.6 million for the same period in 2021. The increased loss was primarily due to higher research and development expenses and general and administrative costs. The company's cash balance as of June 30, 2022, was $53.0 million.

PDS Biotechnology reported a net loss of $8.5 million, or $0.32 per share, for the first quarter of 2022. Research and development expenses increased to $5.2 million, and the company's cash balance as of March 31, 2022, was $58.9 million.

PDS Biotechnology reported a net loss of approximately $16.9 million for the year ended December 31, 2021. The company highlighted clinical progress on its lead oncology candidate, PDS0101, and the initiation of a Phase 2 clinical study by Mayo Clinic. They also strengthened their balance sheet by adding more than $52 million in 2021.

PDS Biotech reported a net loss of $7.0 million, or $(0.24) per basic and diluted share, for the three months ended September 30, 2021. The company's cash and cash equivalents were approximately $69.7 million as of September 30, 2021.

PDS Biotech reported a net loss of $0.6 million for Q2 2021, a significant improvement compared to the $2.9 million loss in Q2 2020, primarily due to a $4.5 million gain from the sale of New Jersey tax benefits. Research and development expenses increased by 95% to $2.8 million, driven by clinical expenses related to VERSATILE-002. The company's cash balance as of June 30, 2021, was $74.7 million, supported by a $52 million public offering.

PDS Biotech reported a net loss of $3.0 million for the first quarter of 2021, with a decrease in both research and development expenses and general and administrative expenses compared to the same period in 2020. The company's cash balance as of March 31, 2021, was approximately $25.0 million.

PDS Biotech reported a net loss of $14.8 million for the year ended December 31, 2020, compared to a net loss of $7.0 million for the previous year. Research and development expenses increased, while general and administrative expenses decreased. The company's cash balance as of December 31, 2020 was $28.8 million.

PDS Biotechnology reported a net loss of $3.9 million, or $0.23 per share, for the third quarter of 2020. The company's cash balance was $33.5 million as of September 30, 2020.

PDS Biotechnology reported a net loss of $2.9 million, or $0.19 per share, for the second quarter of 2020. Research and development expenses totaled $1.4 million, while general and administrative expenses were $1.5 million. The company's cash balance as of June 30, 2020, was $16.9 million.

PDS Biotechnology reported a net loss of $4.0 million for the first quarter of 2020, with research and development expenses increasing by 91% compared to the same period in 2019. The company's cash balance as of March 31, 2020, was approximately $21.0 million, which includes net proceeds from a public offering in February 2020.

PDS Biotechnology reported a net loss of approximately $6.9 million for the year ended December 31, 2019. Research and development expenses increased by approximately 634%, and general and administrative expenses increased by approximately 294%. The company's cash balance as of December 31, 2019, was approximately $12.2 million.